Literature DB >> 18374151

Sex-based differences in vascular repair with bone marrow cell therapy: relevance of regulatory and Th2-type cytokines.

A G Zenovich1, A Panoskaltsis-Mortari, G J Caron, A G Kolb, R Fremming, W D Nelson, D A Taylor.   

Abstract

OBJECTIVES: There are differences in symptoms, risk stratification, and efficacy of pharmacological treatments between men and women with coronary artery disease (CAD). The results of clinical studies of cell therapy in CAD patients are mixed. The relevance of sex to response to cell therapy is unknown. We investigated sex-based differences in response to bone marrow mononuclear cells (BM-MNCs) in atherosclerotic apoliproprotein E-knockout (ApoE -/-) mice.
METHODS: Twenty-three male and 27 female ApoE -/- mice fed on a high-fat diet received four intravenous BM-MNC injections (C57BL6/J mice) starting at 14 weeks of age; male or female BM-MNCs were administered. Thirteen male and 20 female atherosclerotic ApoE -/- mice received vehicle. Aortic plaque burden (%), recipient bone marrow progenitor cell profiles (FACS-LSR II, FlowJo) and 22 circulating cytokine panel (LINCOplex) were quantified and analyzed statistically (SSPS, P < or 5).
RESULTS: Quantitative and semiquantitative results are presented. Increased G-CSF levels correlated with plaque reduction (r = -.86, P = .0004). G-CSF was clustered with IL-15.
CONCLUSIONS: Female but not male BM-MNCs exhibited atheroprotection in male atherosclerotic ApoE -/- mice. Plaque lesions did not attenuate atherosclerosis in female ApoE -/- mice with BM-MNCs of either donor sex. An increase in regulatory and in Th2-type response may be required for atheroprotection. Sex-based differences in vascular repair have implications for cell therapy trials in CAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374151     DOI: 10.1016/j.transproceed.2008.01.040

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  11 in total

1.  Proceedings from the scientific symposium: Sex differences in cardiovascular disease and implications for therapies.

Authors:  C Noel Bairey Merz; Saralyn Mark; Barbara D Boyan; Alice K Jacobs; Prediman K Shah; Leslee J Shaw; Doris Taylor; Eduardo Marbán
Journal:  J Womens Health (Larchmt)       Date:  2010-06       Impact factor: 2.681

2.  Building solutions for cardiovascular disease in women.

Authors:  Micheline M Resende; Doris A Taylor
Journal:  Tex Heart Inst J       Date:  2013

3.  Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Authors:  Ariadna Contreras; Aaron F Orozco; Micheline Resende; Robert C Schutt; Jay H Traverse; Timothy D Henry; Dejian Lai; John P Cooke; Roberto Bolli; Michelle L Cohen; Lem Moyé; Carl J Pepine; Phillip C Yang; Emerson C Perin; James T Willerson; Doris A Taylor
Journal:  Basic Res Cardiol       Date:  2016-11-23       Impact factor: 17.165

Review 4.  Genomics of premature atherosclerotic vascular disease.

Authors:  David Seo; Pascal Goldschmidt-Clermont; Pascal Goldschidt-Clermont; Omaida Velazquez; Gary Beecham
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

5.  Langerhans cell deficiency impairs Ixodes scapularis suppression of Th1 responses in mice.

Authors:  Diana L Vesely; Durland Fish; Mark J Shlomchik; Daniel H Kaplan; Linda K Bockenstedt
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

6.  Relation between objective measures of atopy and myocardial infarction in the United States.

Authors:  Renee Jaramillo; Richard D Cohn; Patrick W Crockett; Kymberly M Gowdy; Darryl C Zeldin; Michael B Fessler
Journal:  J Allergy Clin Immunol       Date:  2012-08-24       Impact factor: 10.793

Review 7.  Cardiovascular cell therapy and endogenous repair.

Authors:  D A Taylor; A G Zenovich
Journal:  Diabetes Obes Metab       Date:  2008-11       Impact factor: 6.577

Review 8.  The battle of the sexes for stroke therapy: female- versus male-derived stem cells.

Authors:  Yuji Kaneko; Travis Dailey; Nathan L Weinbren; Jessica Rizzi; Cyrus Tamboli; Julie G Allickson; Nicole Kuzmin-Nichols; Paul R Sanberg; David J Eve; Naoki Tajiri; Cesar V Borlongan
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-05-01       Impact factor: 4.388

Review 9.  Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine.

Authors:  Faisal A Arain; Fatima H Kuniyoshi; Ahmed D Abdalrhim; Virginia M Miller
Journal:  Circ J       Date:  2009-09-04       Impact factor: 2.993

Review 10.  Adult stem cell transplantation: is gender a factor in stemness?

Authors:  Naoki Tajiri; Kelsey Duncan; Mia C Borlongan; Mibel Pabon; Sandra Acosta; Ike de la Pena; Diana Hernadez-Ontiveros; Diego Lozano; Daniela Aguirre; Stephanny Reyes; Paul R Sanberg; David J Eve; Cesar V Borlongan; Yuji Kaneko
Journal:  Int J Mol Sci       Date:  2014-08-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.